Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Clinical trial NCT01088048 · COMPLETED
Trial details
- NCT number
- NCT01088048
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-03-25
- Primary completion
- 2015-04-28
- Enrollment
- 241
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.